Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE IncellDx, Inc.

PORTLAND, Ore., Oct. 30, 2018 /PRNewswire/ -- Sirona Dx, a leader in high complexity genomics and proteomics services, announced today the launch of Oncocyst PD-L1, an assay using IncellDx technology that detects and quantifies abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry and bioinformatics. The algorithm also uses aneuploidy/DNA content in cells from the bladder, markers often detected by fluorescence in situ hybridization (FISH) and read using microscopy. The new high throughput assay is non-subjective and can be performed in less than 3 hours.

"The ability to batch large numbers of samples to determine the PD-L1 and DNA content status on abnormal urine cytology specimens represents a major advantage over technologies that require subjective microscopic assessment and dark rooms to read FISH," reports Dr. Nasry Yassa, CEO, Sirona Dx. "We are committed to additional assay development projects with InCellDx to leverage their innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers."

"We are delighted to announce a partnership with Sirona Dx for our novel platform of single cell proteomic and genomic assays using flow cytometry and CTC platforms. With simultaneous 30+ marker capabilities and DNA content on individual cells, we are driving personalized medicine to the cellular level addressing the profound tumor heterogeneity in cancer," added Bruce K. Patterson MD, CEO of IncellDx, Inc.

The two companies look forward to presenting the Oncocyst PD-L1 study data at the IncellDx Corporate Symposia, Wednesday, October 31st, at the Association of Molecular Pathology Meeting in San Antonio TX.

About Sirona Dx
Sirona Dx is a technical CRO founded to accelerate the pace of targeted therapy development to improve outcomes for cancer patients. Bridging silos between Dx manufacturers, translational clinical research, and clinical service labs Sirona Dx collaborates with leading platform providers to offer pharmaceutical and clinical research clients early access to advanced technologies.

Sirona Dx operates out of a CLIA certified laboratory facility in Portland, Oregon and offers specialized high complexity genomics and proteomics services supporting pharmaceutical companies with their drug discovery and development programs.

About IncellDx
IncellDx, Inc., located in San Carlos, California, USA is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA in situ hybridization, and DNA cell cycle analysis on flow cytometers, microfluidic devices, and microscope slides.


Sirona Dx
Nasry Yassa
Chief Executive Officer
503 442 3580

Chris Meda
Chief Business Officer


©2017 PR Newswire. All Rights Reserved.